We are thrilled to announce that Explicyte will be attending the AACR annual meeting this year in Orlando, to share our latest developments and translational research works.
A new anti-PD1 resistant mouse sarcoma model, ovarian cancer ascites as a remarkable tool for translational research or our GeoMx platform to support your spatial transcriptomics programs... check out our best highlights of 2022!
Discover our latest publication, titled Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer!
Discover how to fully exploit the mixed leukocyte reaction assay for assessing immunotherapeutics on dendritic cell function and mediated immune response.
Discover our latest article, titled Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma.
We very much look forward to attending the @Society for Immunotherapy of Cancer Annual Meeting in Boston from November 8 to 12, and to showcasing our recent research works through our posters. Plan to stop by to talk of them and about your research programs.
Discover our latest paper, titled Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
Discover our latest publication, which helps predict the survival of cancer patients treated with immune checkpoint inhibitors.
Here is our latest publication, titled A novel gut-restricted small molecule TLR2 agonist enhances immune checkpoint inhibitor efficacy in a preclinical mouse fibrosarcoma tumor model.
Discover our main news for the first half of 2022! Hear about the great opportunity that is our partnership with Domain Therapeutics, new cutting-edge platforms for biomarker translational research as well as our newest featured publication!
Here is our latest publication, titled Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small cell lung cancer.
Ovarian cancer ascites are a remarkable opportunity to improve your translational research and therapeutic testing!